RAPT Therapeutics Receives HSR Clearance for GSK Acquisition, Addresses Shareholder Lawsuits
RAPT has more than doubled off its 52-week low of $5.665.
Summary
RAPT Therapeutics filed an amendment to its Schedule 14D-9, announcing the satisfaction of a key regulatory condition for its acquisition by GSK and disclosing new shareholder lawsuits challenging prior disclosures.
Key Events · M&A and Partnerships · RAPT
-
HSR Act Waiting Period Expired
The waiting period under the HSR Act expired on February 23, 2026, satisfying a key regulatory condition for the tender offer by GSK to acquire RAPT Therapeutics. This significantly de-risks the acquisition's completion.
-
Shareholder Lawsuits and Demand Letters Disclosed
The company disclosed two new shareholder complaints filed in New York and twelve demand letters from purported stockholders, challenging certain disclosures in the original Schedule 14D-9 related to the acquisition. The company denies the allegations but is voluntarily supplementing disclosures to avoid delay.
-
Supplemental Financial Opinion Details
The filing includes additional details and amendments to J.P. Morgan's fairness opinion, including specifics on the discounted cash flow analysis, premia analysis, and analyst price targets, as well as J.P. Morgan's compensation and relationships with GSK.
Analysis · RAPT · Life Sciences
This amendment provides a critical update on the pending acquisition by GSK, confirming the expiration of the HSR Act waiting period. This removes a significant regulatory hurdle, increasing the certainty of the deal's completion. The disclosure of new shareholder lawsuits and demand letters introduces a potential, albeit denied by the company, risk of delay or increased costs, which investors should monitor. The supplemental details regarding J.P. Morgan's fairness opinion offer additional transparency on the valuation process.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.5% of the 1055 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RAPT was trading at $57.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $5.67 to $57.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.